- Pharmaceutically active compounds
-
Compounds of formula (I) wherein: R1 and R19 independently represent hydrogen, alkyl C1-6, alkoxy C1-6, alkylthio C1-6, halogen, hydroxyl or amino; R2 represents H or alkyl; R3 represents phenyl, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, or a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O,N, and S, which phenyl or heterocyclic aromatic ring may be optionally substituted by alkyl C1-6, alkoxy C1-6, haologen, hydroxyl, alkylthio C1-6, cyano, trifluoromethyl, nitro, hydroxymethyl, amino, a group --(CH2)c NHCO2 R10, a group --(CH2)c NR5 R6, or a group --CO2 R11 ; or R3 represents hydrogen or alkyl C1-8, which alkyl group may be optionally substituted by amino or a group --NHCO2 R10 ; R4 represents hydrogen or alkyl C1-6; or R3 and R4 taken together represent a group (CH2)a Z(CH2)b ; c represents an integer 0 to 2; and pharmaceutically acceptable salts thereof, have been found to be useful as a pharmaceuticals. The compounds may especially be used in the treatment of inflammatory disorders.
- -
-
-
- Process for producing 2,6-difluorobenzonitrile
-
A process for producing 2,6-difluorobenzonitrile comprises reducing a chloro fluorobenzonitrile selected from 3-chloro-2,6-difluorobenzonitrile, 3,5-dichloro-2,6-difluorobenzonitrile or a mixture thereof by hydrogen gas in the presence of a palladium or platinum catalyst at a temperature of 0° to 200° C.
- -
-
-